




FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>   (Use several sheets if necessary)		98,365-B1	09/772,819
	<b>Applicant:</b>  Kathleen E. Rodgers, et al.		
	<b>Filing Date:</b>  January 30, 2001	<b>Group:</b>  1654	

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	1	5,686,116	11-11-1997	Bockman, et al.			
	2	5,656,598	8-12-1997	Dunstan, et al.			
	3	5,464,439	11-7-1995	El Gendler			
	4	5,013,649	5-7-1991	Wang, et al.			
	5	5,700,774	12-23-1997	Hattersley, et al.			
	6	5,736,372	4-7-1998	Vacanti, et al.			
	7	5,015,629	5-14-1991	Gere diZerega			
	8	5,629,292	5-13-97	Rodgers, et al.			
	9	5,693,616	12-2-1997	Krstenansky, et al.			
	10	5,607,474	3-4-1997	Athanasίου, et al.			
	11	5,916,207	6-29-1999	Harumitsu Toyoda			
	12	5,324,775	6-28-1994	Rhee, et al.			
	13	5,443,515	8-22-1995	Cohen, et al.			
	14	5,171,273	12-15-1992	Silver, et al.			
	15	4,642,120	2-10-1987	Nevo, et al.			
	16	5,053,050	10-1-1991	Samuel Itay			

EXAMINER	DATE CONSIDERED
	09/30/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 98,365-B1	Serial No. 09/772,819
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		<b>Applicant:</b> Kathleen E. Rodgers, et al.	
		<b>Filing Date:</b> January 30, 2001	<b>Group:</b> 1654



## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
<i>[Signature]</i>	17	5,955,430	9-21-1999	Rodgers, et al.			
<i>[Signature]</i>	18	5,834,432	11-10-1998	Rodgers, et al.			
<i>[Signature]</i>	19	5,716,935	2-10-1998	Rodgers, et al.			

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<i>[Signature]</i>	20	WO 99/46285	9-16-1999	PCT				
	21	WO 96/39164	12-12-1996	PCT				
	22	WO 96/14858	5-23-1996	PCT				
	23	WO 88/00205	1-14-1988	PCT				
	24	WO 95/08565	3-30-1995	PCT				
	25	WO 95/08337	3-30-1995	PCT				
	26	WO 96/15795	30 May 1996	PCT				
	27	WO 96/40090	19 December 1996	PCT				
<i>[Signature]</i>	28	WO 98/26795	25 June 1998	PCT				

EXAMINER	DATE CONSIDERED
<i>[Signature]</i>	09/30/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		98,365-B1	09/772,819
	<b>Applicant:</b>  Kathleen E. Rodgers, et al.		
	<b>Filing Date:</b>  January 30, 2001	<b>Group:</b>  1654	



<del>29</del>	WO 98/32457	30 July 1998	PCT				
<del>30</del>	WO 98/33813	06 August 1998	PCT				
<del>31</del>	WO 99/26644	03 June 1999	PCT				
<del>32</del>	WO 99/31125	24 June 1999	PCT				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).**

<del>33</del>	Okazaki, et al., (1996), Ann. Rheum. Dis., 55: pp. 181-186.
<del>34</del>	Price, et al., (1982), Proc. Natl. Acad. Sci. USA, 79: pp. 7734-7738.

EXAMINER	DATE CONSIDERED <i>09/30/04</i>
----------	---------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

98,365-B1

Serial No.

09/772,819

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)



**Applicant:**

Kathleen E. Rodgers, et al.

**Filing Date:**

January 30, 2001

**Group:**

1654

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).**

35	Georgescu, et al., (1988), In Vitro Cell. Dev. Biol., 24: pp. 1015-1022.
36	Kream, et al., (1985), Endocrinol., 116: pp. 296-302.
37	Lowry, et al., (1954), J. Biol. Chem., 207: pp. 19-37.
38	Kato, et al., (1985), J. Cell Biol., 100: pp. 477-485.
39	Halton, et al., (1997), J. of Endocrinol., 152: pp. 5-10.
40	Lamparter, et al., (1998), Physiol., 175: pp. 89-98.
41	Hiruma, et al., (1997), Biochem and Biophys. Res. Commun., 230: pp. 176-178.
42	Hagiwara, et al., (1998), J. Of Endocrinology, 156: pp. 543-550.
43	Speth and Kim, (1990), BBRC, 169: pp. 997-1006.
44	Catalioto, et al., (1994), Eur. J. Pharmacol., 256: pp. 93-97.
45	Bryson, et al., (1992), Eur. J. Pharmacol., 225: pp. 119-127.
46	Janiak, et al., (1992), Hypertension, 20: pp. 737-745.
47	Prescott, et al., (1991), Am. J. Pathol., 139: pp. 1291-1295.
48	Kauffman, et al., (1991), Life Sci., 49: pp. 223-228.
49	Viswanathan, et al., (1992), Peptides, 13: pp. 783-786.
50	Kimura, et al., (1992), BBRC, 187: pp. 1083-1090.
51	Pfeilschifter, et al., (1992), Eur. J. Pharmacol., 225: pp. 57-62.
52	Jaiswal, et al., (1992), Hypertension 19(Supp. II): II-49-II-55.
53	Edwards and Stack, (1993), J. Pharmacol. Exper. Ther., 266: pp. 506-510.


EXAMINER

DATE CONSIDERED

09/30/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.


<b>FORM PTO-1449</b> (Rev. 2-32)	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b>	<b>Serial No.</b>
<b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>		98,365-B1	09/772,819
(Use several sheets if necessary)		<b>Applicant:</b>	
		Kathleen E. Rodgers, et al.	
		<b>Filing Date:</b>	<b>Group:</b>
		January 30, 2001	1654


**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).**

54	Jaiswal, et al., (1993), J. Pharmacol. Exper. Ther., 265: pp. 664-673.
55	Jaiswal, et al., (1991), Hypertension, 17: pp. 1115-1119.
56	Portsi, et al., (1994), Br. J. Pharmacol., 111: pp. 652-654.
57	Regoli, et al., (1974), Pharmacological Reviews, 26: pp. 69-123.
58	Clouston, et al., (1988), Genomics, 2: pp. 240-248.
59	Kageyama, et al., (1984), Biochemistry, 23: pp. 3603-3609.
60	Ohkubo, et al., (1983), Proc. Natl. Acad. Sci., 80: pp. 2196-2200.
61	Dzau, et al., (1989), J. Mol. Cell. Cardiol., 21: S7 (Supp III).
62	Berk, et al., (1989), Hypertension, 13: pp. 305-314.
63	Kawahara, et al., (1988), BBRC, 150P pp. 52-59.
64	Naftilan, et al., (1989), J. Clin. Invest., 83: pp. 1419-1423.
65	Taubman, et al., (1989), J. Bio. Chem., 264: 526-530.
66	Nakahara, et al., (1992), BBRC, 184: pp. 811-818.
67	Stouffer and Owens, (1992), Circ. Res., 70: page 820-828.
68	Wolf, et al., (1992), Am. J. Pathol., 140: pp. 95-107.
69	Bell and Madri, et al., (1990), Am. J. Pathol., 137: pp. 7-12.
70	Fernandez, et al., (1985), J. Lab. Clin. Med., 105: page 141-145.
71	LeNoble, et al., (1991), Eur. J. Pharmacol., 195: pp. 305-306.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
	09/30/04

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No.	Serial No.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		98,365-B1	09/772,819	
 (Use several sheets if necessary)		Applicant:		
Kathleen E. Rodgers, et al.			Filing Date:	
January 30, 2001		Group:		1654

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

72	Slovik, et al., (1986), J. Bone & Min. Res., 1: pp. 377-381.
73	Toriumi, et al., (1991), Arch. Otolaryngol Head Neck Surg., 117: pp. 1101-1112.
74	Gerhart, et al., (1991), Trans Orthop Res Soc., 16: page 172.
75	Wozney, et al., (1993), Bone Morphogenetic Proteins and Their Gene Expression, in Cellular and Molecular Biology of Bone, (Academic Press, Inc.), pp. 131-167.
76	Wozney, et al., (1988), Science, 242: pp. 1528-1534.
77	Sporn, et al., (1987), J. Cell. Biol., 105: pp. 1039-1045.
78	Centrella, et al., (1987), J. Biol. Chem., 262: pp. 2869-2874.
79	Chenu, et al., (1988), Proc. Natl. Acad. Sci. U.S.A., 85: pp. 5683-5687.
80	Kiebzak, et al., (1988), J. Bone Min. Res., 3: pp. 439-446.
81	Joyce, et al., (1990), J. Cell. Biol., 110: pp. 2195-2207.
82	Noda and Camilliere, (1989), Endocrinology, 124: pp. 2991-2994.
83	Dijke, et al., Bio/Technology, (1989), 7: pp. 793-798.
84	Hagiwara, et al., (1998), "Regulation of bone metabolism by vasoactive peptides" Saishin Igaku, Vol: 53 (6) pp. 1289-1294 (Translated from Japanese).

EXAMINER	DATE CONSIDERED
	09/30/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		98,365-B1	09/772,819
		<b>Applicant:</b>  Kathleen E. Rodgers, et al.	
		<b>Filing Date:</b>  January 30, 2001	<b>Group:</b>  1654



## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	1.	Pierre Schelling, et al., (1979), J. Cell. Physiol., "Effects of Angiotensin II and Angiotensin II Antagonist Saralasin on Cell Growth and Renin in 3T3 and SVST3 Cells", Vol: 98, pp. 503-514

EXAMINER	DATE CONSIDERED
	09/30/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if no in conformance and not considered. Include copy of this form with next communication.